Alnylam Pharmaceuticals, Inc. or Novavax, Inc.: Who Leads in Yearly Revenue?

Biotech Giants: Alnylam vs. Novavax Revenue Showdown

__timestampAlnylam Pharmaceuticals, Inc.Novavax, Inc.
Wednesday, January 1, 20145056100030659000
Thursday, January 1, 20154109700036250000
Friday, January 1, 20164715900015353000
Sunday, January 1, 20178991200031176000
Monday, January 1, 20187490800034288000
Tuesday, January 1, 201921975000018662000
Wednesday, January 1, 2020492853000475598000
Friday, January 1, 20218442870001146290000
Saturday, January 1, 202210374180001598951000
Sunday, January 1, 20231828292000556382000
Loading chart...

Igniting the spark of knowledge

Alnylam vs. Novavax: A Revenue Race Over the Years

In the dynamic world of biotechnology, Alnylam Pharmaceuticals and Novavax have been pivotal players. Since 2014, these companies have shown remarkable growth trajectories, with Alnylam's revenue surging by over 3,500% by 2023. Novavax, on the other hand, experienced a meteoric rise in 2021, with revenues peaking at nearly 1.6 billion, a staggering 5,000% increase from 2014. However, by 2023, Alnylam reclaimed the lead, boasting revenues 3.3 times higher than Novavax. This shift underscores the volatile yet promising nature of the biotech industry, where innovation and market dynamics can rapidly alter the competitive landscape. As these companies continue to innovate, investors and industry watchers eagerly anticipate the next chapter in this revenue rivalry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025